Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Antimicrob Agents Chemother. 2018 Oct 24;62(11):e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov.


Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8 mg/liter) and resistant (MIC, >8 mg/liter). The key supportive data from pharmacokinetic/pharmacodynamic analyses, in vitro surveillance, including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials are collated and analyzed here.

Trial registration: ClinicalTrials.gov NCT00752219 NCT01499290 NCT01500239 NCT01726023 NCT01595438 NCT01599806 NCT01644643 NCT01808092.

Keywords: MIC breakpoints; ceftazidime-avibactam.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Azabicyclo Compounds / pharmacology*
  • Ceftazidime / pharmacology*
  • Clinical Trials as Topic
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Enterobacteriaceae / drug effects*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Pseudomonas aeruginosa / drug effects*


  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • Ceftazidime

Associated data

  • ClinicalTrials.gov/NCT00752219
  • ClinicalTrials.gov/NCT01499290
  • ClinicalTrials.gov/NCT01500239
  • ClinicalTrials.gov/NCT01726023
  • ClinicalTrials.gov/NCT01595438
  • ClinicalTrials.gov/NCT01599806
  • ClinicalTrials.gov/NCT01644643
  • ClinicalTrials.gov/NCT01808092